Cargando…

Caveolin-1 regulates hormone resistance through lipid synthesis, creating novel therapeutic opportunities for castration-resistant prostate cancer

Caveolin-1 (Cav-1) is overexpressed in aggressive and metastatic prostate cancer (PCa) and induces PCa cell proliferation. Androgens mediate lipid synthesis through acetyl-CoA carboxylase-1 (ACC1) and fatty acid synthase (FASN). We investigated the Cav-1-mediated lipid synthesis in the development o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Karantanos, Theodoros, Karanika, Styliani, Wang, Jianxiang, Yang, Guang, Dobashi, Masato, Park, Sanghee, Ren, Chengzhen, Li, Likun, Basourakos, Spyridon P., Hoang, Anh, Efstathiou, Eleni, Wang, Xuemei, Troncoso, Patricia, Titus, Mark, Broom, Bradley, Kim, Jeri, Corn, Paul G., Logothetis, Christopher J., Thompson, Timothy C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5216801/ https://www.ncbi.nlm.nih.gov/pubmed/27331874 http://dx.doi.org/10.18632/oncotarget.10113

Ejemplares similares

Enzalutamide and CXCR7 inhibitor combination treatment suppresses cell growth and angiogenic signaling in castration‐resistant prostate cancer models
por: Luo, Yong, et al.
Publicado: (2018)

DNA damage response and prostate cancer: defects, regulation and therapeutic implications
por: Karanika, Styliani, et al.
Publicado: (2014)

Novel anti-androgen receptor signaling agents: Understanding the mechanisms of resistance
por: Karanika, Styliani, et al.
Publicado: (2014)

GLIPR1-ΔTM synergizes with docetaxel in cell death and suppresses resistance to docetaxel in prostate cancer cells
por: Karanika, Styliani, et al.
Publicado: (2015)

Immune response after laparoscopic colectomy for cancer: a review
por: Karanika, Styliani, et al.
Publicado: (2013)

976. Development and Validation of a Risk Score for Predicting Cardiovascular Events in HIV-Infected Patients
por: Karanika, Styliani, et al.
Publicado: (2019)

Development and Validation of the HIV-CARDIO-PREDICT Score to Estimate the Risk of Cardiovascular Events in HIV-Infected Patients
por: Karanika, Styliani, et al.
Publicado: (2023)

Human Immunodeficiency Virus and Clonal Hematopoiesis
por: Vorri, Stamatia C., et al.
Publicado: (2023)

Enzalutamide-Resistant Progression of Castration-Resistant Prostate Cancer Is Driven via the JAK2/STAT1-Dependent Pathway
por: Luo, Yong, et al.
Publicado: (2021)

Caveolin-1 and -2 regulate cell motility in castration-resistant prostate cancer
por: Kamibeppu, Toyoharu, et al.
Publicado: (2018)

Caveolin-1-mediated sphingolipid oncometabolism underlies a metabolic vulnerability of prostate cancer
por: Vykoukal, Jody, et al.
Publicado: (2020)

Resistance to MET/VEGFR2 Inhibition by Cabozantinib Is Mediated by YAP/TBX5-Dependent Induction of FGFR1 in Castration-Resistant Prostate Cancer
por: Koinis, Filippos, et al.
Publicado: (2020)

Simvastatin delays castration-resistant prostate cancer metastasis and androgen receptor antagonist resistance by regulating the expression of caveolin-1
por: Gao, Yingying, et al.
Publicado: (2019)

Targeting of CYP17A1 Lyase by VT-464 Inhibits Adrenal and Intratumoral Androgen Biosynthesis and Tumor Growth of Castration Resistant Prostate Cancer
por: Maity, Sankar N., et al.
Publicado: (2016)

Current perspectives on bone metastases in castrate-resistant prostate cancer
por: Logothetis, Christopher, et al.
Publicado: (2018)

Large Extracellular Vesicle Characterization and Association with Circulating Tumor Cells in Metastatic Castrate Resistant Prostate Cancer
por: Gerdtsson, Anna S., et al.
Publicado: (2021)

Mitosis Phase Enrichment with Identification of Mitotic Centromere-Associated Kinesin As a Therapeutic Target in Castration-Resistant Prostate Cancer
por: Sircar, Kanishka, et al.
Publicado: (2012)

Prostate cancer castrate resistant progression usage of non-canonical androgen receptor signaling and ketone body fuel
por: Labanca, Estefania, et al.
Publicado: (2021)

The combination of serum insulin, osteopontin, and hepatocyte growth factor predicts time to castration-resistant progression in androgen dependent metastatic prostate cancer- an exploratory study
por: Dayyani, Farshid, et al.
Publicado: (2016)

Effective Combinatorial Immunotherapy for Castration Resistant Prostate Cancer
por: Lu, Xin, et al.
Publicado: (2017)

Histopathology of castration-resistant prostate cancer confirms changes in bone metastasis during radium-223 treatment: A case report
por: Dobashi, Masato, et al.
Publicado: (2020)

Identification of a novel prostate cancer biomarker, caveolin-1: Implications and potential clinical benefit
por: Corn, Paul G, et al.
Publicado: (2010)

Impact of Time to Castration Resistance on Cytoreductive Radiotherapy in Metastatic Castration-Resistant Prostate Cancer
por: Mai, Lixin, et al.
Publicado: (2020)

Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment
por: Subudhi, Sumit K, et al.
Publicado: (2021)

Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer
por: Chi, Kim N., et al.
Publicado: (2023)

Bone health effects of androgen-deprivation therapy and androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer
por: Hussain, Arif, et al.
Publicado: (2020)

Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate Cancer()()
por: Qiao, Yuanyuan, et al.
Publicado: (2016)

Targeting molecular resistance in castration-resistant prostate cancer
por: Chandrasekar, Thenappan, et al.
Publicado: (2015)

Mechanisms of resistance in castration-resistant prostate cancer (CRPC)
por: Chandrasekar, Thenappan, et al.
Publicado: (2015)

Editorial: Response and Resistance in Castration-Resistant Prostate Cancer
por: de Leeuw, Renée, et al.
Publicado: (2020)

Caveolin-1, a stress-related oncotarget, in drug resistance
por: Wang, Zhiyu, et al.
Publicado: (2015)

Nonmetastatic Castration-Resistant Prostate Cancer
por: Hong, Jun Hyuk, et al.
Publicado: (2014)

Darolutamide For Castration-Resistant Prostate Cancer
por: Bastos, Diogo A, et al.
Publicado: (2019)

Real-World Treatment Patterns in Metastatic Castration-Resistant Prostate Cancer Across Europe (France, Germany, Italy, Spain, and the United Kingdom) and Japan
por: Leith, Andrea, et al.
Publicado: (2022)

Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer
por: Mahon, K L, et al.
Publicado: (2015)

ERG induces taxane resistance in castration-resistant prostate cancer
por: Galletti, Giuseppe, et al.
Publicado: (2014)

Enzalutamide-resistant castration-resistant prostate cancer: challenges and solutions
por: Tucci, Marcello, et al.
Publicado: (2018)

Caveolin-1 Endows Order in Cholesterol-Rich Detergent Resistant Membranes
por: Raggi, Carla, et al.
Publicado: (2019)

Novel Dormancy Mechanism of Castration Resistance in Bone Metastatic Prostate Cancer Organoids
por: Lee, Sanghee, et al.
Publicado: (2022)

Optimal treatment for castration-resistant prostate cancer
por: Izumi, Kouji, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_m3688f6lq8q852m5d9qhdse9nt